Technology | January 20, 2010

First MRA Contrast Agent for AIOD Enters U.S. Market

Ablavar has an MRA indication to evaluate aortoiliac occlusive disease.

January 20, 2010 - The first FDA-cleared contrast imaging agent for use with a magnetic resonance angiography (MRA) indication to evaluate aortoiliac occlusive disease (AIOD) and suspected peripheral vascular disease enters the U.S. market today.

AIOD is a type of peripheral vascular disease that occurs when arteries, which carry blood from the heart to the lower limbs, become narrowed or blocked. This lack of blood supply can result in pain, infection and even loss of limbs[i]. 
 
In Phase 3 clinical studies, Ablavar, the contrast agent that Lantheus Medical Imaging launched today, demonstrated statistically greater sensitivity (detecting disease when present) compared with noncontrast MRA[ii]. These studies, which supported the U.S. Food and Drug Administration (FDA) approval of Ablavar, show that MRA images using Ablavar provided diagnostic accuracy comparable to conventional X-ray angiography,[iii],[iv] an invasive procedure which involves insertion of a catheter into the arteries in the upper thigh (groin area) or arm[v].
 
“Ablavar provides distinct advantages over X-ray angiography, the current standard of care in diagnosing AIOD,” said Mark G. Hibberd, M.D., Ph.D., senior medical director, Global Medical Affairs, Lantheus Medical Imaging, Inc. “Ablavar provides high resolution images comparable to conventional X-ray angiography (the current gold standard), which offers radiologists a clear, enhanced visualization of patients’ arteries. However, Ablavar is given in a single, low dose injection, does not require catheter insertion into a patient’s arteries, and does not expose patients to ionizing radiation, all of which are tangible benefits to patients.”

According to E. Kent Yucel, M.D., FACR, chairman of radiology, Tufts Medical Center, the new contrast agent "may provide clinicians performing vascular imaging with more comprehensive, three-dimensional diagnostic information to improve patient treatment decisions and care."

The introduction of the MRA imaging agent extends Lantheus Medical's product portfolio in the radiology and peripheral vascular disease markets and adds to its diagnostic imaging agents for MRI, SPECT, PET and echocardiography imaging modalities.

Ablavar is approved in 37 countries outside the United States and has been used in nearly 90,000 patients to date.
Contraindications: History of a prior allergic reaction to a gadolinium-based contrast agent. Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate

References:
[i] Vascular Web. Society for Vascular Surgery. "Aortoiliac Occulsive Disease." http://www.vascularweb.org/patients/NorthPoint/Aortoiliac_Occlusive_Disease.html. Assessed Oct. 26, 2009.
[ii] Data on file, Lantheus Medical Imaging Inc.
[iii] Goyen M, Edelman M, Perreault P, et al. "MR Angiography of Aortoiliac Occulsive Disease: A Phase III Study of the Safety and Effectiveness of the Blood-Pool Contrast Agent MS-325." Radiology. 2005; 236(3):825-833.
[iv] Rapp JH, Wolff SD, Quinn SF, et al. "Aortoiliac Occulsive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-Enhanced MR Angiography – Multicenter Comparative Phase III Study." Radiology. 2005; 236(1):71-78.
[v] American Heart Association. "What is Coronary Angiography?" http://www.americanheart.org/presenter.jhtml?identifier=11222. Assessed on Oct. 26, 2009.
[vi] The Imaging Market Guide (U.S. Edition 2009), Arlington Medical Resources Inc. Malvern, Pa..
[vii] National Heart, Lung, and Blood Institute. National Institutes of Health. "Other Names for Peripheral Arterial Disease." http://www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_onames.html. Assessed March 30, 2009.
[viii] National Heart, Lung, and Blood Institute. National Institutes of Health. "Who Is At Risk for Peripheral Arterial Disease?" http://www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_risk.html. Assessed March 30, 2009.

For more information: www.ablavar.com and www.lantheus.com

Related Content

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Merit Medical Announces Advanced Interventional Cardiology Transradial Intervention Education Course
News | Radial Access| August 23, 2017
Merit Medical Systems Inc. will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij,...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Virtual Phantoms Inc. Releases VirtualDose-IR
Technology | Radiation Dose Management| August 07, 2017
Virtual Phantoms Inc. announced the release of VirtualDoseIR, a tool for assessing organ dose from interventional...
Moffitt Cancer Center Enhances Patient Care with Toshiba Medical's Infinix-i 4-D
News | Interventional Radiology| August 03, 2017
Cancer patients at Moffitt Cancer Center in Tampa, Fla., now have access to advanced diagnostic imaging for fast and...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init